Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th
In connection to this year’s major cancer congress ASCO (American Society of Clinical Oncology (https://www.asco.org/)) in Chicago in June, Redeye brings […]
English
Isofol announces that an abstract with new research resultshas been published for this year’s ASCO congress in Chicago
Isofol Medical AB (publ) announces that a scientific abstract has been published for this year’s annual Congress of the American
Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process
In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the United States Food and Drug
Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018
Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related genes in tumours with progression-free
Isofol Medical has selected arfolitixorin-dose for the phase III pivotal study ISO-CC-007
The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for an adult male) is based
Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®
Isofol Medical AB (publ) today announce that the company will in the future be adopting the generic name arfolitixorin for
Isofol reports successful outcome from the scientific advice with the EMA
Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines Agency (EMA) regarding its candidate
Isofol’s CEO, directors and employees converts stock – and employee options and subscribe shares for SEK 7 655 136
The incentive program consisting of stock – and employee options in Isofol Medical AB, which was initiated in 2012 with
Positive treatment results with Modufolin® (arfolitixorin) will be published at a cancer congress (ASCO) in the US
Prior to this year’s Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology (ASCO), the worlds leading oncology
Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin® agreed
Isofol Medical AB (publ), developing Modufolin®(arfolitixorin) as treatment for advanced colorectal cancer, has had a successful regulatory meeting with the